Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases: Correlations with Estrogen Receptors α and β

 

 Buy Article Permissions and Reprints

Abstract

Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56 % vs. 44.4 %); 2) IGF-IR expression in primary tumors was associated with negative node status (p < 0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p < 0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.

References

• 1 Sasco A J, Kaaks R, Little R E. Breast cancer: occurrence, risk factors and hormone metabolism.  Expert Rev Anticancer Ther. 2003;  3 546-562
  CrossrefPubMedGoogle Scholar
• 2 Surmacz E. Function of the IGF-I receptor in breast cancer.  J Mammary Gland Biol Neoplasia. 2000;  5 95-105
  CrossrefPubMedGoogle Scholar
• 3 Sachdev D, Yee D. The IGF system and breast cancer.  Endocr Relat Cancer. 2001;  8 197-209
  CrossrefPubMedGoogle Scholar
• 4 Yee D. Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer.  J Mamm Gland Biol Neopl. 2000;  5 07-115
  PubMedGoogle Scholar
• 5 Pollak M. Insulin-like growth factor physiology and cancer risk.  Eur J Cancer. 2000;  36 1224-1228
  CrossrefPubMedGoogle Scholar
• 6 Turner B C, Haffty B G, Narayanan L, Yuan J, Havre P A, Gumbs A A, Kaplan L, Burgaud J L, Carter D, Baserga R, Glazer P M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation.  Cancer Res. 1997;  57 3079-3083
  PubMedGoogle Scholar
• 7 Dunn S E, Hardman R A, Kari F W, Barrett J C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.  Cancer Res. 1997;  57 2687-2693
  PubMedGoogle Scholar
• 8 Gooch J L, van den Berg C L, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects.  Breast Cancer Res Treat. 1999;  56 1-10
  CrossrefPubMedGoogle Scholar
• 9 Mauro L, Salerno M, Morelli C, Boterberg T, Bracke M E, Surmacz E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression.  J Cell Physiol. 2003;  194 108-116
  CrossrefPubMedGoogle Scholar
• 10 Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.  Cancer Res. 2001;  61 6747-6754
  PubMedGoogle Scholar
• 11 Guvakova M A, Surmacz E. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin.  Exp Cell Res. 1999;  251 244-255
  CrossrefPubMedGoogle Scholar
• 12 Pennisi P A, Barr V, Nunez N P, Stannard B, Le Roith D. Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype.  Cancer Res. 2002;  62 6529-6537
  PubMedGoogle Scholar
• 13 Guvakova M A, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells.  Exp Cell Res. 1997;  231 149-162
  CrossrefPubMedGoogle Scholar
• 14 Doerr M, Jones J. The roles of integrins and extracellular matrix proteins in the IGF-IR-stimulated chemotaxis of human breast cancer cells.  J Biol Chem. 1996;  271 2443-2447
  CrossrefPubMedGoogle Scholar
• 15 Dunn S E, Ehrlich M, Sharp N JH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J C. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion and metastasis of breast cancer.  Cancer Res. 1998;  58 3353-3361
  PubMedGoogle Scholar
• 16 Surmacz , E . Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor.  Oncogene. 2003;  22 6589-6597
  CrossrefPubMedGoogle Scholar
• 17 Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components.  J Biol Chem. 2000;  275 35 893-35 901
  PubMedGoogle Scholar
• 18 Fournier B, Gutzwiller S, Dittmar T, Matthias T G, Steenbergh T, Matthias P. Estrogen receptor (ER)αlpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J. Biol.  Chem.. 2001;  276 35 444-35 449
  PubMedGoogle Scholar
• 19 Jackson J G, White M F, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.  J Biol Chem. 1998;  273 9994-10 003
  CrossrefPubMedGoogle Scholar
• 20 Lee A V, Jackson J G, Gooch J L, Hilsenbeck , SG , Coronado-Heinsohn E, Osborne C K, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.  Mol Endocrin. 1999;  10 787-796
  PubMedGoogle Scholar
• 21 Mauro L, Salerno M, Panno M L, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Ando S. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells.  Biochem Biophys Res Commun. 2001;  288 85-689
  PubMedGoogle Scholar
• 22 Molloy C A, May F EB, Westley B R. Insulin receptor substrate 1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line.  J Biol Chem. 2000;  275 12 565-12 571
  PubMedGoogle Scholar
• 23 Morelli C, Garofalo C, Bartucci M, Surmacz E. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.  Oncogene. 2003;  22 4007-4016
  CrossrefPubMedGoogle Scholar
• 24 Stewart A J, Johnson M D, May F E, Westley B R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.  J Biol Chem. 1990;  265 21 172-21 178
  PubMedGoogle Scholar
• 25 Kleinman D, Karas M, Roberts C T Jr, LeRoith D, Phillip M, Segev Y, Levy J, Sharoni Y. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol.  Endocrinology. 1995;  136 2531-2537
  CrossrefPubMedGoogle Scholar
• 26 Salerno M, Sisci D, Mauro L, Guvakova M A, Ando S, Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells.  Int J Cancer. 1999;  81 299-304
  CrossrefPubMedGoogle Scholar
• 27 Guvakova M A, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.  Cancer Res. 1997;  57 2606-2610
  PubMedGoogle Scholar
• 28 Chan T W, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.  Clin Cancer Res. 2001;  7 2545-2554
  PubMedGoogle Scholar
• 29 Huynh H, Nickerson T, Yang X, Pollak M. Regulation of insulin-like growth factor I receptor by the pure antiestrogen ICI 182,780.  Clin Cancer Res. 1996;  265 2037-2042
  PubMedGoogle Scholar
• 30 Freiss G, Puech C, Vignon F. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells.  Mol Endocrinol. 1998;  12 568-579
  CrossrefPubMedGoogle Scholar
• 31 Parisot J P, Hu X F, DeLuise M, Zalcberg J R. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line.  Br J Cancer. 1999;  79 693-700
  CrossrefPubMedGoogle Scholar
• 32 Peyrat J P, Bonneterre J. Type 1 IGF receptor in human breast diseases.  Breast Cancer Res Treat. 1992;  22 59-67
  CrossrefPubMedGoogle Scholar
• 33 Pezzino V, Papa V, Milazzo G, Gliozzo B, Russo P, Scalia P L. Insulin-like growth factor-I (IGF-I) receptors in breast cancer.  Ann N Y Acad Sci. 1996;  784 189-201
  PubMedGoogle Scholar
• 34 Happerfield L C, Miles D W, Barnes D M, Thomsen L L, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue.  J Pathol. 1997;  183 412-417
  PubMedGoogle Scholar
• 35 Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer.  Int J Cancer. 2000;  89 506-513
  CrossrefPubMedGoogle Scholar
• 36 Railo M J, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients.  Eur J Cancer. 1994;  30 307-311
  CrossrefPubMedGoogle Scholar
• 37 Foekens J A, Portengen H, Janssen M, Klijn J G. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer.  Cancer. 1989;  63 2139-2147
  PubMedGoogle Scholar
• 38 Jammes H, Peyrat J P, Ban E, Vilain M O, Haour F, Djiane J, Bonneterre J. Insulin-like growth factor 1 receptors in human breast tumour: localization and quantification by histo-autoradiographic analysis.  Br J Cancer. 1992;  66 248-253
  PubMedGoogle Scholar
• 39 Resnik J L, Reichart D B, Huey K, Webster N JG, Seely B L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer.  Cancer Res. 1998;  58 1159-1164
  PubMedGoogle Scholar
• 40 Peyrat J P, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors.  Cancer Res. 1988;  48 6429-6433
  PubMedGoogle Scholar
• 41 Bonneterre J, Peyrat J P, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer.  Cancer Res. 1990;  50 6931-6935
  PubMedGoogle Scholar
• 42 Papa V, Gliozzo B, Clark G M, McGuire W L, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine I D, Pezzino V. Insulin-like growth factor I receptors are overexpressed and predict a low risk in human breast cancer.  Cancer Res. 1993;  53 3736-3740
  PubMedGoogle Scholar
• 43 Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine I D, Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.  Clin Cancer Res. 1999;  5 1935-1944
  PubMedGoogle Scholar
• 44 Pekonen F, Partanen S, Makinen T, Rutanen E M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer.  Cancer Res. 1988;  48 1343-1347
  PubMedGoogle Scholar
• 45 Lee A V, Hilsenbeck S G, Yee D. IGF-I system components as prognostic markers in breast cancer.  Breast Cancer Res Treat. 1998;  47 295-302
  CrossrefPubMedGoogle Scholar
• 46 Sepp-Lorenzino L, Rosen N, Lebwohl D. Insulin and insulin-like growth factor signaling are defective in MDA-MB-468 human breast cancer cell line.  Cell Growth Differen. 1994;  5 1077-1083
  PubMedGoogle Scholar
• 47 Peyrat J P, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Djiane J, Demaille A. Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines.  Bull Cancer. 1989;  76 311-319
  PubMedGoogle Scholar
• 48 Jackson J G, Yee D. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells.  Growth Horm IGF Res. 1999;  9 280-289
  PubMedGoogle Scholar
• 49 Arteaga C L, Kitten L J, Coronado E B, Jacobs S, Kull F C Jr, Allred D C, Osborne C K. Blockade of the type I somatomedin receptor inhibits growth of human breats cancer cells in athymic mice.  J Clin Invest. 1989;  84 1418-1423
  PubMedGoogle Scholar
• 50 Dunn S E, Ehrlich M, Sharp N, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett J. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion and metastasis of breast cancer.  Cancer Res. 1998;  58 3353-3361
  PubMedGoogle Scholar
• 51 Bloom H JG, Richardson W W. Histological grading and prognosis in breast cancer.  Br J Cancer. 1957;  11 359-377
  PubMedGoogle Scholar
• 52 Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human.  Nucleic Acids Res. 1998;  26 3505-3512
  CrossrefPubMedGoogle Scholar
• 53 Pettersson K, Delaunay F, Gustafsson J A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling.  Oncogene. 2000;  19 4970-4978
  CrossrefPubMedGoogle Scholar
• 54 Pettersson K, Grandien K, Kuiper G G, Gustafsson J A. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha.  Mol Endocrinol. 1997;  11 1486-1496
  CrossrefPubMedGoogle Scholar
• 55 Roger P, Sahla M E, Makela S, Gustafsson J A, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.  Cancer Res. 2001;  61 2537-2541
  PubMedGoogle Scholar
• 56 Hall J M, McDonnell D P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.  Endocrinology. 1999;  140 5566-5578
  CrossrefPubMedGoogle Scholar
• 57 Jarvinen T A, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.  Am J Pathol. 2000;  156 29-35
  PubMedGoogle Scholar
• 58 Jensen E V, Cheng G, Palmieri C, Saji S, Makela S, van Noorden S, Wahlstorm T, Warner M, Coombes R C, Gustafsson J A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer.  Proc Natl Acad Sci USA. 2001;  98 15 197-15 202
  PubMedGoogle Scholar
• 59 Speirs V, Kerin M J. Prognostic significance of oestrogen receptor beta in breast cancer.  Br J Surg. 2000;  87 405-409
  CrossrefPubMedGoogle Scholar
• 60 Speirs V, Malone C, Walton D S, Kerin M J, Atkin S L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.  Cancer Res. 1999;  59 5421-5424
  PubMedGoogle Scholar
• 61 Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7.  Oncogene. 2003;  22 5011-5020
  CrossrefPubMedGoogle Scholar
• 62 Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J A, Toi M. Clinical impact of assay of estrogen receptor beta cx in breast cancer.  Breast Cancer. 2002;  9 303-307
  CrossrefPubMedGoogle Scholar
• 63 Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma.  Hum Pathol. 2001;  32 940-944
  CrossrefPubMedGoogle Scholar
• 64 Vidal O, Kindblom L G, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone.  J Bone Miner Res. 1999;  14 923-929
  PubMedGoogle Scholar
• 65 Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J A, Toi M. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.  Cancer Res. 2002;  62 4849-5483
  PubMedGoogle Scholar
• 66 Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.  Int J Cancer. 2000;  88 733-736
  CrossrefPubMedGoogle Scholar
• 67 Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines.  Breast Cancer Res Treat. 2002;  71 249-255
  CrossrefPubMedGoogle Scholar

E. Surmacz, Ph. D. 

Kimmel Cancer Center

Thomas Jefferson University · 233S 10 St. · BLSB 631 · Philadelphia, PA 19107 · USA

Phone: + 1 (215) 5034512

Fax: + 1 (215) 9230249

Email: eva.surmacz@jefferson.edu